Epigenetic Alterations in Pancreatic Cancer
DOI:
https://doi.org/10.17140/POJ-1-e002Keywords:
KRAS, TP53, SMAD4, and CDKN2AAbstract
Pancreatic cancer is the fourth leading cause of cancer death and is predicted to be the second leading cause in a decade in the US. Despite more than 50 years of research and therapeutic development, pancreatic cancer still has a median survival rate of 6 months and a 5-year overall survival around 5%. Therefore, there is an urgent need to better understand the mechanism of pancreatic cancer development, as well as to discover new biomarkers for early diagnosis, prognosis, and therapeutic targets.
References
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518: 495-501. doi: 10.1038/nature14169
Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and thera-peutic targets. Nature communications. 2015; 6: 6744. doi: 10.1038/ncomms7744
Wang L, Tsutsumi S, Kawaguchi T, et al. Whole-exome sequencing of human pancreatic cancers and characterization of ge-nomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome research. 2012; 22: 208-219. doi: 10.1101/ gr.123109.111
Quilichini E, Haumaitre C. Implication of epigenetics in pancreas development and disease. Best Practice & Research Clinical Endocrinology & Metabolism. 2015; 29: 883-898. doi: 10.1016/j.beem.2015.10.010
Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein & Cell. 2014; 5: 265-296. doi: 10.1007/s13238- 014-0031-6
Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature Reviews Genetics. 2012; 13: 484- 492. doi: 10.1038/nrg3230
Guo M, Jia Y, Yu Z, et al. Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. Discovery Medicine. 2014; 17: 67-73.
Park JY, Helm J, Coppola D, Kim D, Malafa M, Kim SJ. MicroRNAs in pancreatic ductal adenocarcinoma. World Journal of Gastroenterology. 2011; 17: 817-827.
Saha A, Wittmeyer J, Cairns BR. Chromatin remodelling: the industrial revolution of DNA around histones. Nature Reviews Molecular Cell Biology. 2006; 7: 437-447. doi: 10.1038/nrm1945
Hakimi AA, Chen YB, Wren J, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European Urology. 2013; 63: 848-854.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.